# Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

> **NCT06695013** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 144 (estimated)

## Conditions studied

- B-NHL
- CART Therapy

## Interventions

- **DRUG:** zanubrutinib
- **DRUG:** CAR-T
- **RADIATION:** Bridging radiotherapy
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT06695013
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2026-11-20
- **Final completion:** 2027-03-20
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06695013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06695013, "Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06695013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*